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Spontaneous intracranial haemorrhage (ICH) is less com-
mon as a cause of stroke than ischaemia, but it has sig-
nificantly worse morbidity and mortality. To some extent
this reflects, the different demographics of the populations
affected, but a lack of effective therapeutic options is also a
contributory factor. Whilst ICH as a result of underlying
vascular malformations or other structural lesions offers
certain neuroradiological and/or neurosurgical possibilities
to prevent recurrence, interventions to reverse damage
caused by the index event remain limited regardless of
aetiology. As a result, current management is mainly sup-
portive and includes reversal of anticoagulation where
appropriate, blood pressure control, prevention of hyper-
glycaemia and pyrexia, and the treatment of emergent
complications, such as seizures.
Anticoagulant and antiplatelet medications are often
associated with ICH and adversely affect outcome. Patients
are treated with these agents for a variety of reasons,
including primary or secondary prevention of cardiac and
cerebral ischaemic events. Historically, there has been a
choice been between aspirin (or other antiplatelet agents)
or a coumarin. However, recently a number of new agents
have been developed (novel oral anticoagulants—NOACs),
and have potential advantages over Warfarin, including a
lower risk of haemorrhagic complications for an equivalent
level of thrombo-embolic risk reduction and the lack of
requirement for international normalised ratio (INR)
monitoring. However, none of the NOACs has a specific
agent to reverse their action in the event of haemorrhagic
complications.
This month, journal club focuses on reversal of drugs
which contribute to or have the potential to worsen ICH.
The first paper reports a randomised-controlled trial of
platelet infusion versus the standard care in patients with
ICH on antiplatelet agents. The second paper is a ran-
domised-controlled trial of fresh frozen plasma versus
prothrombin complex concentrate in the reversal of war-
farin-associated ICH. Finally, we review an observational
study of ICH associated with NOACs, focussing on prog-
nostic factors and effectiveness of haemostatic treatments.
Platelet transfusion versus standard care
after acute stroke due to spontaneous cerebral
haemorrhage associated with antiplatelet therapy
(PATCH): a randomised, open-label, phase 3 trial
Observational studies have suggested that antiplatelet
drugs contribute to early haematoma expansion and death
in the setting of ICH. In addition, there is an independent
association between antiplatelet drugs and death from ICH.
This randomised, controlled, multicentre trial aimed to
compare the addition of platelet transfusion to the standard
care.
This European trial included adults on aspirin, clopi-
dogrel, dipyridamole, and carbasalate. ICH was confirmed
on first available imaging modality—CT or MRI. Platelets
were delivered within 6 h of stroke onset, and 90 min of
imaging. Patients with poor premorbid function, suspected
focal vascular lesions, extradural or subdural haemor-
rhages, planned neurosurgical intervention, intraventricular
extension, concurrent anticoagulants, infratentorial loca-
tion, or coma (GCS\8) were excluded. Randomisation
& N. P. Robertson
robertsonnp@cardiff.ac.uk
1 Institute of Psychological Medicine and Clinical
Neuroscience, Cardiff University, University Hospital of
Wales, Heath Park, Cardiff CF14 4XN, UK
123
J Neurol (2016) 263:1468–1470
DOI 10.1007/s00415-016-8198-9
was by coin toss; patients were given 1 unit of platelets or 2
if the patient was taking ADP inhibitors. NIHSS was used
to grade stroke severity and modified Rankin Scoring
(mRS, blinded to treatment allocation) to score outcome.
Patents had a 24 h follow-up scan—haemorrhage volume
was calculated and checked by blinded raters. Primary
outcome was the mRS category change, with secondary
outcomes of poor outcome (mRS 3–6), ICH volume,
complications of treatment, or complications of the acute
event. Data were analysed in an intention to treat basis. An
ordinal linear regression analysis was used, changed from a
binary outcome analysis prior to statistical analysis [poor
outcome (mRS 4–6) versus non-poor outcome] to increase
power.
190 participants were included—97 received platelets
and 93, standard care. There were no baseline differences
between the groups. 42 were excluded (32 for intraven-
tricular haemorrhage, 7 for insufficient imaging, 2 for
infratentorial location, and 1 was not taking antiplatelets
agents). The primary outcome showed a significant wors-
ening with platelets (OR 1.84, 95 % CI 1.10–3.08;
p = 0.0200). Serious adverse events were more frequent in
the group receiving platelets. No changes were seen on any
of the pre-specified subgroup analyses (country, haema-
toma volume, type of antiplatelet agent).
Comment. The sample size for the study was relatively
small, with a comparatively high percentage of exclusions;
nevertheless, the result seems consistent regardless of the
analysis method used, as the secondary outcome also
proved significant. The rationale for excluding patients
potentially undergoing neurosurgical intervention was not
clear and adherence to antiplatelet agents was not mea-
sured. Despite these caveats, it is clear that platelet trans-
fusion should be abandoned.
Baharoglu MI et al. (2016) Lancet (Epub ahead of print).
Fresh frozen plasma versus prothrombin complex
concentrate in patients with intracranial
haemorrhage related to vitamin K antagonists
(INCH): a randomised trial
ICH secondary to warfarin was historically reversed using
fresh frozen plasma (FFP), but its status as a blood product
limited use in some patient groups and carried associated
risks of transfusion reactions and infection. PCC has been
shown to be superior owing to faster restoration of normal
INR. The two treatments have never been compared in a
head to head trial in the setting of ICH.
This randomised-controlled trial recruited adults with an
INR of 2.0 or greater diagnosed with a new ICH (within
12 h of neurological symptoms). Patients with a
known/suspected vascular malformation, contraindications
to large volume transfusion (for example cardiac failure),
or poor clinical status (premorbid mRS [2 or GCs \6)
were excluded. Data analysis was blinded, as treatment
administration could not be. Randomisation was by com-
puter. All participants were given 10 mg of vitamin K, and
the trial intervention was delivered within 1 h of diagnostic
CT. Haematoma volume was assessed at 3, 24, and 72 h
post treatment. The primary endpoint was INR\1.3 at 3 h
post infusion. Secondary endpoints were clinical (death,
haematoma expansion, NIHSS at discharge, and time to
target INR) and functional (EQ5D, mRS, Barthel index,
Glasgow outcome scale). Groups were compared using the
Chi-squared test.
Twenty-six participants were given FFP and 28 PCC;
four had withdrawn (no differences were seen on a sensi-
tivity analysis). The legal authority demanded termination
based on an interim analysis showing a worse haematoma
expansion in the FFP group. No differences in mortality
were seen. Forty-three serious adverse events were repor-
ted, although no significant differences were seen between
the groups. In a post-hoc analysis, 65 % of the PCC group
achieved target INR, whilst none of the FFP group had.
Comment. This trial, although stopped early and con-
taining small numbers, is highly suggestive of PCC’s
superiority over FFP. However, it may be considered
unfortunate that clinical endpoints (death and disability)
were not primary endpoints in the trial and that the trial
was stopped before it could be determined if any significant
differences in these outcomes could be determined.
Steiner T et al. (2016) Lancet Neurol 15:566–573.
Early clinical and radiological course,
management, and outcome of intracerebral
haemorrhage related to new oral anticoagulants
Despite the apparent lower frequency of haemorrhage
compared with the coumarins, a major limitation of
NOACs is the lack of specific reversal therapy if haemor-
rhage does occur. Our knowledge of the severity and fre-
quency of complications in ‘real world’ settings as opposed
to clinical trials is also limited at present. This prospective
cohort study aimed to address these gaps.
Participants were recruited from 38 German hospitals
between February 1, 2012 and December 31, 2014. Par-
ticipants were included if they were aged 18 or over, were
taking an NOAC, and had ICH at baseline. Investigations
and management were left to the treating physician. Clin-
ical data included the NIHSS (National Institute of Health
Stroke Score) at 24, 48, and 72 h, mRS (premorbid score,
at admission, at discharge and at 90 day follow-up) and the
CHA2DS2-VASC and HASBLED scores. Radiological
variables were also included—haematoma expansion
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([33 % increase in volume, or absolute increase of 6 ml),
which required follow-up imaging within 3–72 h. Groups
were compared using Chi-squared tests, Fisher exact test,
Mann–Whitney U test, and associations were sought using
logistic regression.
Sixty-one patients were enrolled from 21 centres. Mena
age was 76.1, and mean NIHSS was 10. Median haema-
toma volume at baseline was 10.8 ml. NIHSS score cor-
related with haematoma volume. Symptom onset to time of
imaging was not correlated with haematoma volume.
Haematoma expansion was seen in 38 % of those who had
follow-up imaging (45 of the 61 participants), and intra-
ventricular expansion occurred in 11 %.
Thirty-seven of 61 patients received PCC. This had no
effect on early haematoma expansion and no difference in
mRS at 90 days, although the intervention group had worse
clinical status and more frequent deep haemorrhages.
Sixteen per cent died as an inpatient, with a 28 % mortality
rate at 3 months. 65 % of survivors had poor outcome
(mRS 3–5). Strong associations were found between
NIHSS score at onset and mRS, as well as baseline hae-
matoma size and mRS.
Comments. It is perhaps unsurprising but never-the-less
disheartening to see a lack of effect for PCC in this setting.
However, it should be noted that these are observational
data, the group receiving reversal therapy were more
unwell, and the numbers were relatively small. A ran-
domised-controlled trial would answer this question more
definitively.
Purrucker JC et al. (2016) JAMA Neurol 73(2):169–177.
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